Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia.
about
Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasiaThe dark side of 5α-reductase inhibitors' therapy: sexual dysfunction, high Gleason grade prostate cancer and depressionCurrent status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH.Recent Advances in Drug Design and Drug Discovery for Androgen- Dependent Diseases.Finasteride induced Gynecomastia: Case report and Review of the LiteratureEffects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation.Androgens and estrogens in skeletal sexual dimorphism.5α-reductase type 1 modulates insulin sensitivity in men.Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice GuidelineEffects of short-term dutasteride and Serenoa repens on perioperative bleeding and microvessel density in patients undergoing transurethral resection of the prostate.Benign prostatic hyperplasia: treatment in primary care.Changes in sexual function in benign prostatic hyperplasia patients taking dutasteride: 1-year follow-up results.Impact of preoperative 5α-reductase inhibitors on perioperative blood loss in patients with benign prostatic hyperplasia: a meta-analysis of randomized controlled trialsDutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hyperplasia.Identification of the patient with enlarged prostate: diagnosis and guidelines for management.Preventing diseases of the prostate in the elderly using hormones and nutriceuticals.Benign prostatic hyperplasia: an insight into current investigational medical therapies.Evidence-based guidelines for the treatment of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary from AURO.itImpact of medical treatments for benign prostatic hyperplasia on sexual function.Dutasteride: a dual 5-alpha reductase inhibitor for the treatment of symptomatic benign prostatic hyperplasia.5alpha-reductase inhibition for men with enlarged prostate.Advances in the development of hormonal modulators for the treatment of benign prostatic hyperplasia.Emerging drugs for the treatment of benign prostatic obstruction.Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor - Dutasteride.Hair restoration approaches for early onset male androgenetic alopecia.Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study.Evaluation of bioequivalence of five 0.1 mg dutasteride capsules compared to one 0.5 mg dutasteride capsule: a randomized study in healthy male volunteers.Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?Androgenetic Alopecia: An Update of Treatment Options.Outline of JUA clinical guidelines for benign prostatic hyperplasia.Finasteride-its impact on sexual function and prostate cancer.Greater extent of prostate inflammation in negative biopsies is associated with lower risk of prostate cancer on repeat biopsy: results from the REDUCE study.Demographic and comorbidity profile of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a real-life clinical setting: Are 5-alpha-reductase inhibitor consumers different?Long-term therapy with the dual 5alpha-reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasia.Preparation, characterization and stability study of dutasteride loaded nanoemulsion for treatment of benign prostatic hypertrophy.Chronic baseline prostate inflammation is associated with lower tumor volume in men with prostate cancer on repeat biopsy: Results from the REDUCE study.Supraphysiological testosterone enanthate administration prevents bone loss and augments bone strength in gonadectomized male and female rats.Emerging drugs for the treatment of benign prostatic hyperplasia.Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men.Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).
P2860
Q24199135-19BCF98A-A272-417E-B739-4BC28CD43004Q24564068-736612A2-2310-44B6-81B0-4985B29BF901Q33602452-93B025A6-38CB-460C-8BDF-1F582ABECF95Q33623428-5B88BBBC-0EDD-4F42-AA00-699C713FA6EDQ34089440-309D6F9D-9C77-4A6E-A54E-4497E12240CFQ34313221-AEA1222B-1888-4F09-9961-5847CA6E1949Q34395346-B4F76D49-DC4C-420A-AE11-CB7AD1AF7F60Q34396472-C4412510-C800-4F24-9DF5-5686A1C2917AQ34604979-C6990FBD-4B6C-40E2-A40C-3C8CB39A5179Q35013421-0222E95A-2032-4A40-96BF-E925CD60C2A8Q35021669-1B03FB63-2C35-4185-B8E5-62817CB988DCQ35407450-56FCCC1A-0B3D-496C-8545-53EA7B49BA86Q35649097-09DDE48D-16DD-40AD-97D9-F59F43B45DCBQ35876383-2796A0FF-4644-4E44-A844-9D443EF589AEQ35945368-9B48BA21-ACF9-41C3-800E-61587060CA7FQ36021075-B791E3DE-910B-4737-B7E2-5FE4EFFC1468Q36300022-3DFB9CE9-50E9-4640-BC62-052A972692E1Q36379355-35D29EAA-E212-423F-8095-EC264A95AE5FQ36409144-4D450CDB-1907-4CEA-8656-B3DA531B9461Q36434305-BDC39BD2-F4CD-412A-BFAA-E1A0626BB6C8Q36892851-1D2ACC98-6E12-4821-A680-7AEFA9876BF6Q36916873-49FC35F0-F251-40FB-B30A-8D779DF301D9Q37743490-C57A6212-ABA8-49AC-A6F2-F44CD3CE7113Q38118357-31F5E959-7157-4043-8EF4-C7B46FB37B5DQ38132841-8260084B-34D4-41BF-9694-CE49CD7270CDQ38170026-AB3A2660-71EF-4D24-8E92-BC9F178742DCQ38418380-8E687A79-863F-4CBD-A1ED-C779F74E7CD4Q38571198-57233232-40AD-453F-A66D-36EBEDE554AEQ38935324-10494B89-0AD6-4256-882B-7C9AA4447B34Q39256832-604E9469-7739-45B7-ADBC-82DFA804232FQ39681594-0CF265E8-E8B2-4C36-B10A-A8A1D369D398Q40967154-044C66B2-B762-450E-9B07-31919496405FQ41709993-E59E04C0-C2E4-42BA-BF3C-C0C817DCAEEBQ42675109-61CB2CCE-60D0-43C2-A914-87E76F1AB5A2Q42701365-909E1039-29CC-4D7B-B441-74F281EE5464Q44130971-4FB8A52E-7AEF-4B2E-ACE4-4461C5228BE9Q46379434-C5E3DE21-652D-410E-8F58-E9B6F5FF3B6AQ47553287-380AEBC2-D88C-4A7D-9B26-858A21A127D3Q49971559-E451BF2B-5FA2-44EF-80C2-539CF9278FA7Q53152507-70BF1F6D-3EF7-4CA8-B526-B630182BBD7C
P2860
Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Safety and tolerability of the ...... benign prostatic hyperplasia.
@ast
Safety and tolerability of the ...... benign prostatic hyperplasia.
@en
type
label
Safety and tolerability of the ...... benign prostatic hyperplasia.
@ast
Safety and tolerability of the ...... benign prostatic hyperplasia.
@en
prefLabel
Safety and tolerability of the ...... benign prostatic hyperplasia.
@ast
Safety and tolerability of the ...... benign prostatic hyperplasia.
@en
P1433
P1476
Safety and tolerability of the ...... benign prostatic hyperplasia.
@en
P2093
Gerald L Andriole
Roger Kirby
P356
10.1016/S0302-2838(03)00198-2
P407
P577
2003-07-01T00:00:00Z